União Europeia - português - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anemia, célula falciforme - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

União Europeia - português - EMA (European Medicines Agency)

accord healthcare s.l.u. - icatibant acetate - angioedemas, hereditário - other hematological agents - icatibant accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (hae) in adults, adolescents and children aged 2 years and older, with c1 esterase inhibitor deficiency.

União Europeia - português - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

União Europeia - português - EMA (European Medicines Agency)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - agentes antitrombóticos - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). segmento st elevação infarto agudo do miocárdio, em combinação com asa em medicamente tratados os pacientes elegíveis para terapia trombolítica. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. para mais informações, por favor consulte a secção 5.

União Europeia - português - EMA (European Medicines Agency)

taw pharma (ireland) limited - cloridrato de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agentes antitrombóticos - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

União Europeia - português - EMA (European Medicines Agency)

tad pharma gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - agentes antitrombóticos - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

União Europeia - português - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

União Europeia - português - EMA (European Medicines Agency)

vanda pharmaceuticals netherlands b.v. - tasimelteon - distúrbios do sono, ritmo circadiano - psicolepticos - hetlioz é indicado para o tratamento do transtorno de sono-vigília sem 24 horas (não-24) em adultos totalmente cegos.

União Europeia - português - EMA (European Medicines Agency)

bayer animal health gmbh - imidacloprido, moxidectin - produtos antiparasitário, inseticidas e repelentes - dogs; cats; ferrets - dogsfor cães que sofrem ou correm o risco de, misto de infecções parasitárias:o tratamento e a prevenção de infestação de pulgas (ctenocephalides felis),o tratamento de morder piolhos (trichodectes canis),o tratamento de orelha a infestação dos ácaros (otodectes cynotis), sarcoptic mange (causada pelo sarcoptes scabiei var. canis), demodicosis (causada pelo demodex canis),a prevenção da dirofilariose doença (l3 e l4 larvas da dirofilaria immitis),o tratamento de circulação de microfilárias (dirofilaria immitis),o tratamento de tegumento cutâneo dirofilariosis (adulto fases de dirofilaria repens)a prevenção cutânea dirofilariosis (l3 larvas da dirofilaria repens),a redução da circulação de microfilárias (dirofilaria repens),a prevenção de angiostrongylosis (l4 larvas e adultos imaturos de angiostrongylus vasorum),o tratamento de angiostrongylus vasorum e crenosoma vulpis,a prevenção de spirocercosis (spirocerca lupi),o tratamento de eucoleus (syn. capillaria) boehmi (adultos),o tratamento do olho verme thelazia callipaeda (adultos),o tratamento de infecções por nematóides gastrointestinais (l4 larvas, imaturos e adultos de toxocara canis, ancylostoma caninum e uncinaria stenocephala, os adultos de toxascaris leonina) e trichuris vulpis). o produto pode ser usado como parte de uma estratégia de tratamento para dermatite de alergia a pulga (fad). catsfor gatos que sofrem ou correm o risco de, misto de infecções parasitárias:o tratamento e a prevenção de infestação de pulgas (ctenocephalides felis),o tratamento de orelha a infestação dos ácaros (otodectes cynotis),o tratamento de notoedric mange (notoedres cati),o tratamento da lungworm eucoleus aerophilus (syn. capillaria aerophila) (adultos),a prevenção de lungworm doença (l3/l4 larvas de aelurostrongylus abstrusus),o tratamento da lungworm aelurostrongylus abstrusus (adultos),o tratamento do olho verme thelazia callipaeda (adultos),a prevenção da dirofilariose doença (l3 e l4 larvas da dirofilaria immitis),o tratamento de infecções por nematóides gastrointestinais (l4 larvas, imaturos e adultos de toxocara cati e ancylostoma tubaeforme). o produto pode ser usado como parte de uma estratégia de tratamento para dermatite de alergia a pulga (fad). ferretsfor furões que sofrem ou correm o risco de, misto de infecções parasitárias:o tratamento e a prevenção de infestação de pulgas (ctenocephalides felis),a prevenção da dirofilariose doença (l3 e l4 larvas da dirofilaria immitis).

União Europeia - português - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tipo 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 para dados disponíveis em diferentes combinações).